Latest Insights

Stay Ahead.

Get Korea Alpha in your inbox.

Korea Alpha infographic showing Bukwang Pharmaceutical's Q3 2026 operating profit growth of 120.7%, with a pharmaceutical manufacturing facility in the background. Korea Alpha financial infographic contrasting Bukwang Pharmaceutical's 17.8% revenue growth with a 22.2% decline in operating profit during the first nine months of 2026. Korea Alpha neuroscience pharmaceutical infographic highlighting 20% growth in Bukwang's CNS strategic-product prescriptions, Latuda commercialization and CP-012 Phase 2 development. Korea Alpha valuation chart comparing Bukwang Pharmaceutical's KRW 3,865 reference share price with its KRW 3,700 estimated fair value, indicating 4.3% downside.
Technology

Bukwang Pharmaceutical Q3 2026: Profit Jumps 121% as R&D Costs Rise

Bukwang Pharmaceutical (003000.KS) reported Q3 2026 revenue of KRW 57.97 billion, up 21.2% year over year, and operating profit of KRW 2.16 billion, up 120.7%. However, nine-month operating profit fell 22.2% as research spending increased. Latuda's commercial growth and Contera Pharma's CP-012 Parkinson's disease program provide long-term opportunities, but sustained profitability remains unproven. Korea Alpha estimates fair value at KRW 3,700 per share, implying 4.3% downside from the October 22 closing price.
↑ Market Impact Mid Read Full Analysis →
October 23, 2026 · 6 min
Kia Sportage SUVs on a city highway, illustrating record Q3 2026 global vehicle sales of 846,764 units, up 7.8% year over year. Kia operating-margin chart comparing the actual Q2 2026 margin of 8.0% with BNK Securities' Q3 estimate of 7.2%, alongside a Sportage SUV. Kia Sportage Hybrid and EV4 vehicles illustrating 61% year-over-year growth in global hybrid retail sales during Q2 2026. Kia share-price comparison chart showing a KRW 108,800 closing price and KRW 188,000 brokerage consensus target, implying 72.8% upside.
Mobility

Kia's Record Q3 2026 Sales Face Margin Test as Analysts Cut Targets

Kia (000270.KS) delivered its strongest third-quarter vehicle sales on record, supported by overseas demand and a region-specific electrification strategy. Yet analysts expect operating margins to retreat from Q2's 8.0% as input costs, sales incentives and vehicle mix weigh on profitability. With Kia's 2026 earnings target increasingly demanding and brokerage price targets moving lower, the next investment catalyst is earnings quality rather than vehicle volume.
↑ Market Impact High Read Full Analysis →
October 23, 2026 · 6 min